Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

NCT03512353 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03512353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03512353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
July 5, 2018
Completion date
January 16, 2020
Enrollment
7 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma